Posted by Michael Wonder on 28 Sep 2018
Eli Lilly migraine drug approved and will be free to patients
28 September 2018 - Amgen, Teva already launched new drugs called CGRP inhibitors.
Eli Lilly got clearance from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
The FDA approved galcanezumab, a so called CGRP inhibitor that will be marketed under the name Emgality, on Thursday. Indianapolis-based Lilly said it will offer the drug at no cost for a year to millions of patients with commercial insurance, a move that reflects increased scrutiny of high prescription costs in the U.S. and fierce competition in a hot treatment area.
